January 28, 2014 | Israeli company Oramed Pharmaceuticals, which is developing a revolutionary insulin pill for diabetics, has filed a request to raise $100 million on Nasdaq. The company is already publicly traded and has shown a rise in stock since its report of a successful trial for its type 1 diabetes treatment.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

AI Startup Helps Doctors Analyze Heart Scans
February 08, 2023

AI Monitors High-Speed Conveyor Belts For Defects
February 08, 2023

Israel Hi-Tech Group In Rescue Mission To Turkey
February 08, 2023

Israeli Startup Tests Cancer Treatment With Pharma Giant
February 07, 2023
Facebook comments